Literature DB >> 25888550

Improving Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer by adding interleukin 2 (IL-2): a mathematical model.

Svetlana Bunimovich-Mendrazitsky1, Sarel Halachmi2, Natalie Kronik3.   

Abstract

One of the treatments offered to non-invasive bladder cancer patients is BCG instillations, using a well-established, time-honoured protocol. Some of the patients, however, do not respond to this protocol. To examine possible changes in the protocol, we provide a platform for in silico testing of alternative protocols for BCG instillations and combinations with IL-2, to be used by urologists in planning new treatment strategies for subpopulations of bladder cancer patients who may benefit from a personalized protocol. We use a systems biology approach to describe the BCG-tumour-immune interplay and translate it into a set of mathematical differential equations. The variables of the equation set are the number of tumour cells, bacteria cells, immune cells, and cytokines participating in the tumour-immune response. Relevant parameters that describe the system's dynamics are taken from a variety of independent literature, unrelated to the clinical trial results assessed by the model predictions. Model simulations use a clinically relevant range of initial tumour sizes (tumour volume) and tumour growth rates (tumour grade), representative of a virtual population of fifty patients. Our model successfully retrieved previous clinical results for BCG induction treatment and BCG maintenance therapy with a complete response (CR) rate of 82%. Furthermore, we designed alternative maintenance protocols, using IL-2 combinations with BCG, which improved success rates up to 86% and 100% of the patients, albeit without considering possible side effects. We have shown our simulation platform to be reliable by demonstrating its ability to retrieve published clinical trial results. We used this platform to predict the outcome of treatment combinations. Our results suggest that the subpopulation of non-responsive patients may benefit from an intensified combined BCG IL-2 maintenance treatment. © The authors 2015. Published by Oxford University Press on behalf of the Institute of Mathematics and its Applications. All rights reserved.

Entities:  

Keywords:  BCG and IL-2 combined therapy; BCG immunotherapy; bladder cancer; immune system cells dynamics; mathematical modelling

Mesh:

Substances:

Year:  2015        PMID: 25888550     DOI: 10.1093/imammb/dqv007

Source DB:  PubMed          Journal:  Math Med Biol        ISSN: 1477-8599            Impact factor:   1.854


  9 in total

1.  Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach.

Authors:  Anat Globerson Levin; Natalie Kronik; Zelig Eshhar; Vladimir Vainstein; Tamar Shiloach; Tova Waks
Journal:  Cancer Immunol Immunother       Date:  2020-03-04       Impact factor: 6.968

2.  Dynamics of Immune Checkpoints, Immune System, and BCG in the Treatment of Superficial Bladder Cancer.

Authors:  Farouk Tijjani Saad; Evren Hincal; Bilgen Kaymakamzade
Journal:  Comput Math Methods Med       Date:  2017-10-26       Impact factor: 2.238

Review 3.  A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors.

Authors:  Anyue Yin; Dirk Jan A R Moes; Johan G C van Hasselt; Jesse J Swen; Henk-Jan Guchelaar
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-08-09

Review 4.  Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm.

Authors:  Vijayalakshmi Chelliah; Georgia Lazarou; Sumit Bhatnagar; John P Gibbs; Marjoleen Nijsen; Avijit Ray; Brian Stoll; R Adam Thompson; Abhishek Gulati; Serguei Soukharev; Akihiro Yamada; Jared Weddell; Hiroyuki Sayama; Masayo Oishi; Sabine Wittemer-Rump; Chirag Patel; Christoph Niederalt; Rolf Burghaus; Christian Scheerans; Jörg Lippert; Senthil Kabilan; Irina Kareva; Natalya Belousova; Alex Rolfe; Anup Zutshi; Marylore Chenel; Filippo Venezia; Sylvain Fouliard; Heike Oberwittler; Alix Scholer-Dahirel; Helene Lelievre; Dean Bottino; Sabrina C Collins; Hoa Q Nguyen; Haiqing Wang; Tomoki Yoneyama; Andy Z X Zhu; Piet H van der Graaf; Andrzej M Kierzek
Journal:  Clin Pharmacol Ther       Date:  2020-08-14       Impact factor: 6.875

5.  Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling.

Authors:  Joseph D Butner; Geoffrey V Martin; Zhihui Wang; Eugene J Koay; Bruna Corradetti; Mauro Ferrari; Nestor Esnaola; Caroline Chung; David S Hong; James W Welsh; Naomi Hasegawa; Elizabeth A Mittendorf; Steven A Curley; Shu-Hsia Chen; Ping-Ying Pan; Steven K Libutti; Shridar Ganesan; Richard L Sidman; Renata Pasqualini; Wadih Arap; Vittorio Cristini
Journal:  Elife       Date:  2021-11-09       Impact factor: 8.140

6.  Cell-Level Spatio-Temporal Model for a Bacillus Calmette-Guérin-Based Immunotherapy Treatment Protocol of Superficial Bladder Cancer.

Authors:  Teddy Lazebnik
Journal:  Cells       Date:  2022-08-02       Impact factor: 7.666

Review 7.  Treatment of non-muscle invasive bladder cancer with Bacillus Calmette-Guerin (BCG): Biological markers and simulation studies.

Authors:  Alex Kiselyov; Svetlana Bunimovich-Mendrazitsky; Vladimir Startsev
Journal:  BBA Clin       Date:  2015-06-10

8.  Stability Analysis of Delayed Immune Response BCG Infection in Bladder Cancer Treatment Model by Stochastic Perturbations.

Authors:  Leonid Shaikhet; Svetlana Bunimovich-Mendrazitsky
Journal:  Comput Math Methods Med       Date:  2018-07-09       Impact factor: 2.238

9.  Furin-responsive triterpenine-based liposomal complex enhances anticervical cancer therapy through size modulation.

Authors:  Yunyan Chen; Mengfei Guo; Ding Qu; Yuping Liu; Jian Guo; Yan Chen
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.